CLLS Q4 2025: $53M Cash Burn Drives Focused Allogeneic CAR-T Execution and Pivotal Milestone Readouts
Selectus (CLLS) enters 2026 with a sharpened clinical focus and a disciplined cash strategy, positioning its allogeneic CAR-T pipeline for pivotal data readouts and commercial inflection. With internal manufacturing validated and two late-stage programs advancing, the company is betting its future on execution and differentiated clinical outcomes in high-need hematologic cancers. Successful interim analyses and partner milestones this year will determine Selectus’s trajectory as a late-stage cell therapy contender.
Summary
- Internal Manufacturing Upside: Selectus’s shift to in-house production improved response rates and gross margin prospects.
- Allogeneic CAR-T Pipeline Advances: Both Lasmacel and Eticel are on track for pivotal data, targeting high unmet need populations.
- Milestone-Heavy 2026: Multiple partner and internal catalysts will define Selectus’s competitive standing this year.
Performance Analysis
Selectus reported a $53 million net decrease in cash, ending 2025 with $211 million in liquidity, driven by focused investment in its two core clinical programs, Lasmacel and Eticel, and operational spend across Paris and Raleigh manufacturing sites. Revenue was positively impacted by AstraZeneca collaboration activities, but the company remains pre-commercial, with near-term value creation tied to clinical and partnership milestones rather than product sales.
Management emphasized rigorous cash discipline and prioritization of late-stage development, enabling a financial runway into the second half of 2027. The operational focus remains on advancing the pivotal Phase II trial for Lasmacel in acute lymphoblastic leukemia (ALL) and the Phase I/II transition for Eticel in non-Hodgkin lymphoma, both targeting heavily pretreated, high-risk patient cohorts. Internal manufacturing was validated with superior efficacy compared to external CDMO-supplied product, a key lever for future gross margin and supply chain control.
- Cash Burn Driven by R&D: The majority of outflows supported clinical advancement and internal manufacturing scale-up.
- Revenue Mix Shaped by Partnerships: AstraZeneca collaboration contributed revenue, underscoring the value of Selectus’s gene editing platform.
- Operational Spend Prioritized for Milestone Delivery: Spend tightly aligned with pivotal readouts and site expansions in North America and Europe.
With no commercial revenue, the company’s valuation and forward trajectory now hinge on delivering pivotal data and unlocking milestone payments from collaborations and licenses.
Executive Commentary
"While others stepped back, Selectus stepped forward. We held the line. We managed our cash with rigor. We invested where it matters, and we kept our teams focused entirely on one thing, delivering clinical results for patients who are running out of time with no therapeutic solution."
Dr. André Choulika, Chief Executive Officer
"We believe our current cash position gives us the financial runway to execute on our pivotal Phase II program for LASMA-Cell and our Phase I for ETI-Cell and deliver two key readouts in Q4 2026... As of December 31st, 2025, our cash, cash equivalents, restricted cash, and fixed-term deposits classified as current financial assets amount to $211 million."
Arthur Strill, Chief Financial Officer and Chief Business Officer
Strategic Positioning
1. Allogeneic CAR-T Clinical Leadership
Selectus is one of the few companies advancing a pivotal phase II allogeneic CAR-T trial in B-cell ALL, targeting patients who have exhausted CD19 CAR-T and other therapies. The off-the-shelf, ready-to-use product design is positioned to address urgent clinical needs where autologous therapies are too slow or infeasible.
2. Internal Manufacturing as a Differentiator
Transitioning manufacturing in-house yielded higher response rates (68% vs 28%) compared to external CDMO, validating process control and supporting future gross margin expansion. This capability is a strategic asset for commercial scalability and supply reliability.
3. Dual Antigen Targeting and Pipeline Breadth
Eticel’s dual targeting of CD20 and CD22 in non-Hodgkin lymphoma is designed to address antigen escape, a key resistance mechanism. Preliminary data show an 88% response rate and 63% complete response, with additional enhancement strategies (low-dose IL-2) under evaluation.
4. Partner Ecosystem and Platform Monetization
Strategic collaborations with Allogene, Iovance, and AstraZeneca provide near-term milestones and validate the gene editing platform’s broader relevance. Upcoming partner data readouts (e.g., Allo501A/Semicel) are potential catalysts for non-dilutive capital and expanded platform credibility.
5. Regulatory and Commercial Pathways
Phase II pivotal readouts and BLA (Biologics License Application) submissions for Lasmacel (2028) and Eticel (2029) set a clear roadmap. Management sees commercial advantage in the off-the-shelf model, enabling rapid site launches and favorable economics compared to autologous CAR-Ts.
Key Considerations
2026 is a pivotal year for Selectus, with multiple clinical, regulatory, and partnership catalysts that will clarify its competitive and financial trajectory. The company’s fate is closely tied to execution on both clinical endpoints and operational scale-up, in a sector with high attrition and capital intensity.
Key Considerations:
- Data Readout Timing: Interim pivotal data for Lasmacel and full Phase I data for Eticel are both expected in Q4 2026, setting up a binary period for value realization or risk crystallization.
- Manufacturing Scale and Quality: Internal production improvements must translate into consistent, scalable output as trials expand and commercialization approaches.
- Partner Milestone Visibility: Allogene and Iovance programs could deliver up to $340 million in milestones, providing non-dilutive funding and external validation.
- Competitive Landscape: The field is crowded and evolving, with in vivo CAR-T and other modalities being closely watched but not yet proven in ultra-refractory settings.
Risks
Execution risk remains high, with clinical, regulatory, and manufacturing hurdles ahead. The company’s liquidity is sufficient through 2027, but further delay or negative data could force capital raises or pipeline reprioritization. Competition from both autologous and emerging in vivo CAR-T modalities, as well as evolving regulatory expectations around lymphodepletion and safety, add further uncertainty.
Forward Outlook
For Q4 2026, Selectus guided to:
- Interim analysis of 40-patient pivotal Phase II Lasmacel trial (eight-week composite endpoint)
- Full Phase I data readout for Eticel, including IL-2 cohort durability and efficacy
For full-year 2026, management expects:
- Multiple partner data readouts (Allogene Semicel, Iovance IOV4001)
- Progression of pivotal trial site openings (targeting ~75 sites in North America and Europe)
Management highlighted that cash runway extends into H2 2027, and that execution against these milestones will shape capital needs and strategic flexibility for 2027 and beyond.
Takeaways
Selectus’s investment case is now binary, with Q4 2026 data determining whether its allogeneic CAR-T platform will move into the commercial and partnering spotlight or face further clinical and financial headwinds.
- Clinical Execution Is Pivotal: The company’s value is now tied to late-stage data and successful transition to pivotal trials, with internal manufacturing as a potential margin lever.
- Partner Milestones Provide Optionality: Up to $340 million in partner-driven milestones offer near-term capital and external validation, but are contingent on partner trial success.
- Competition and Modality Evolution: Investors should monitor the impact of in vivo CAR-T and other new entrants, but Selectus’s focus on ultra-refractory patients and off-the-shelf delivery remains a key differentiator for now.
Conclusion
2026 will be a make-or-break year for Selectus, with clinical, operational, and partnership milestones converging to define its place in the next wave of cell therapy. Execution on pivotal trials and manufacturing scale-up will be decisive for long-term value creation.
Industry Read-Through
Selectus’s progress underscores the shift toward allogeneic and off-the-shelf cell therapies, with internal manufacturing and platform partnerships as critical levers for both economics and pipeline breadth. The focus on heavily pretreated, high-need patients sets a new bar for clinical differentiation, while the ability to secure non-dilutive capital from strategic collaborations is a blueprint for other biotech players. As in vivo CAR-T and next-generation gene editing evolve, the industry’s attention will remain on which modalities can combine speed, scalability, and clinical depth in the most difficult-to-treat populations.